Validation of Molecular Diagnostic Thecnologies for Lung Cancer Patients. Center for Excellence in Precision Medicine (NIRVANA), Pfizer Chile
Más información
Fecha de publicación: | 2015 |
Objetivos: | The validation of more sensitive and high throughput technologies for the study of non-small cell lung cancer genomics alterations, and the generation of comprehensive, high quality, clinical, pathological, and genomics data in Chile, Brazil, and Peru. |
Año de Inicio/Término: | 2015-2018 |
Financiamiento/Sponsor: | CORFO |
Rol del Usuario: | PERSONAL DE APOYO |
URL: | https://clinicaltrials.gov/ct2/show/NCT03220230 |
DOI: |
13CEE2-21602 |